Introduction Solriamfetol is a dopamine/norepinephrine reuptake inhibitor approved in the EU for excessive daytime sleepiness (EDS) associated with narcolepsy. This real-world study characterises outcomes following solriamfetol initiation.

Methods SURWEY is an ongoing retrospective chart review (Germany, France, Italy). Patients (≥18 years old, EDS due to narcolepsy, stable solriamfetol dose, ≥6 weeks of treatment) were classified by solriamfe- tol initiation: changeover (from existing EDS medications), add-on (to current EDS medication), or new- to-therapy (no current/prior EDS medication). Epworth Sleepiness Scale (ESS) scores, patient/physician impressions of improvement, and adverse events (AEs) were assessed.

Results Among 78 German patients (36.9±13.9 years old; 56% female, 57% with cataplexy), changeo- ver was most common (n=43), followed by add-on (n=19) and new-to-therapy (n=8). Final follow-up was 15.9±7.0 weeks after initiation. Overall, ESS scores were 17.6±3.1 (n=61) at initiation and 13.6±3.8 at follow-up (n=51), indicating improvement of EDS (improvements similar across subgroups). Most patients perceived slight/strong improvements in their condition (physician report, 94%; patient report, 91%; results similar across subgroups). Common AEs: headache (9%), decreased appetite (6%), insomnia (6%).

Conclusion In this real-world cohort of German patients with narcolepsy, EDS improved across all subgroups with solriamfetol treatment. AEs were consistent with those reported in clinical trials.

Support Jazz Pharmaceuticals.